Cargando…

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

BACKGROUND: In the EMPOWER‐Lung 1 trial (ClinicalTrials.gov, NCT03088540), cemiplimab conferred longer survival than platinum‐doublet chemotherapy for advanced non–small cell lung cancer (NSCLC) with programmed cell death‐ligand 1 (PD‐L1) ≥50%. Patient‐reported outcomes were evaluated among trial pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gümüş, Mahmut, Chen, Chieh‐I, Ivanescu, Cristina, Kilickap, Saadettin, Bondarenko, Igor, Özgüroğlu, Mustafa, Gogishvili, Miranda, Turk, Haci M., Cicin, Irfan, Harnett, James, Mastey, Vera, Naumann, Ulrike, Reaney, Matthew, Konidaris, Gerasimos, Sasane, Medha, Brady, Keri J. S., Li, Siyu, Gullo, Giuseppe, Rietschel, Petra, Sezer, Ahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092585/ https://www.ncbi.nlm.nih.gov/pubmed/36308296 http://dx.doi.org/10.1002/cncr.34477

Ejemplares similares

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
por: Feliciano, Josephine Louella, et al.
Publicado: (2023)

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
por: Paul, Eleanor, et al.
Publicado: (2021)

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
por: Gogishvili, Miranda, et al.
Publicado: (2022)

Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report
por: Taban, Hakan, et al.
Publicado: (2022)

Qualitative Patient Interviews to Characterize the Human Burden of Advanced Basal Cell Carcinoma Following Hedgehog Pathway Inhibitor Treatment
por: Konidaris, Gerasimos, et al.
Publicado: (2023)

The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients
por: Özdede, Murat, et al.
Publicado: (2023)

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
por: Rischin, Danny, et al.
Publicado: (2021)

Cemiplimab combined with chemotherapy versus chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis
por: Zhu, Gaofeng, et al.
Publicado: (2023)

Cemiplimab-Induced Alopecia Areata
por: Piraccini, Bianca Maria, et al.
Publicado: (2023)

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Cemiplimab-Associated Sinusoidal Obstruction Syndrome
por: Sarsour, Nadeen Y., et al.
Publicado: (2023)

Cemiplimab for cutaneous squamous cell carcinoma, basal cell carcinoma, non-small cell lung cancer
Publicado: (2022)

A Case of Multifocal Skin Metastases from Lung Cancer Presenting with Vasculitic-type Cutaneous Nodule
por: Babacan, Nalan Akgul, et al.
Publicado: (2015)

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer
por: Denis, Chloé, et al.
Publicado: (2021)

Intravascular squamous cell carcinoma treated with cemiplimab
por: Rose, Alexander N., et al.
Publicado: (2021)

Self‐resolving bullous pemphigoid induced by cemiplimab
por: Molle, Mattia Fabio, et al.
Publicado: (2022)

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
por: Lu, Tingting, et al.
Publicado: (2023)

Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations
por: Ahn, Jeffrey, et al.
Publicado: (2023)

The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients
por: Ozdemir, Nesligul, et al.
Publicado: (2021)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
por: Yang, Feng, et al.
Publicado: (2021)

PNS250 How to Deal with COVID-19-Related Intercurrent Events on Trial Estimands for Patient-Reported Outcomes (PRO) Objectives
por: Skaltsa, K., et al.
Publicado: (2020)

Reproductive cancer risk factors among relatives of cancer patients in a tertiary oncology center
por: Atta, Nooria, et al.
Publicado: (2019)

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
por: Goodman, D.T.
Publicado: (2022)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
por: Zargham, Hanieh, et al.
Publicado: (2022)

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?
por: Boziou, Maria, et al.
Publicado: (2023)

Vogt-Koyanagi-Harada-like Syndrome Induced by Checkpoint Inhibitor Cemiplimab
por: Huang, Ye, et al.
Publicado: (2023)

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
por: Van Meerhaeghe, T., et al.
Publicado: (2022)

Peripheral Neuropathy in Sézary Syndrome: Coincidence or a Part of the Syndrome?
por: Karadağ, Yeşim S., et al.
Publicado: (2013)

Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
por: Guven, Deniz C., et al.
Publicado: (2021)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis
por: Paccaly, Anne J., et al.
Publicado: (2021)

Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis
por: Grace de Lima, Stacy, et al.
Publicado: (2023)

Combined cemiplimab and radiotherapy for advanced basal cell carcinoma: A case report
por: Sarfaraz, Sidra, et al.
Publicado: (2023)

Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
por: Kitano, Shigehisa, et al.
Publicado: (2020)

Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
por: Li, Junlong, et al.
Publicado: (2018)

Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma
por: Marukian, Nareh Valerie, et al.
Publicado: (2020)

Drug-Associated Eosinophilic Fasciitis: A Case of Eosinophilic Fasciitis Secondary to Cemiplimab Therapy
por: Boppana, Sri Harsha, et al.
Publicado: (2021)

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives
por: Mager, Layna, et al.
Publicado: (2023)

Efficacy of Cemiplimab in a Patient Affected by Cutaneous Squamous Cell Carcinoma and Myelodysplastic Syndrome
por: Proietti, Ilaria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e24l29st7ld71blabnnes9fg9d